Topical Androgen Receptor Inhibitors Market size is anticipated to reach USD 221.8 Million by the end of 2036, growing at a CAGR of 14% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of topical androgen receptor inhibitors was USD 40 Million. The need for potent topical androgen receptor inhibitors is driven by the increasing incidence of androgenetic alopecia and hirsutism, two disorders associated with androgen receptors. AGA is becoming more commonplace worldwide because of a combination of lifestyle, hormone fluctuations, and genetics. A greater number of patients are seeking effective treatments, such as topical androgen receptor inhibitors, as a result of this rising incidence. Excessive hair growth in women, frequently with a male pattern, is a symptom of hirsutism. Hormonal imbalances and conditions such as polycystic ovarian syndrome (PCOS) can aggravate hirsutism. Data from the World Health Organization (WHO) in June 2023 indicate that 8–13% of women of reproductive age have PCOS. Worldwide, up to 70% of afflicted women go undetected.
People are looking for ways to control their undesired hair growth as awareness of these conditions increases, which is driving up demand for topical androgen receptor inhibitors. The increasing prevalence of androgen-related conditions is a significant growth factor for the topical androgen receptor inhibitors market.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~ 14% |
|
Base Year Market Size (2023) |
~ USD 40 Million |
|
Forecast Year Market Size (2036) |
~ USD 221.8 Million |
|
Regional Scope |
|
Indication (Androgenetic Alopecia, Hirsutism)
The Androgenetic alopecia segment in the topical androgen receptor inhibitors market is anticipated to hold a share of 55% during the forecast period. Several factors affect the growth of Topical Androgen Receptor Inhibitors (TARI) in the Androgenetic Alopecia (AGA) segment. People are looking for effective remedies, like TARI, as a result of growing awareness of AGA treatments that are available, as well as rising concerns about appearance and the desire to seem younger. Personalized medicine and patient-centered healthcare are popular trends that support the creation of individualized treatment plans. TARI fits in with this patient-centered strategy as a targeted treatment for AGA. Additionally, people now have localized, non-invasive therapy alternatives due to the development and marketing of topical formulations like Clascoterone that can block androgen receptors. The market in the AGA segment is expanding as a result of all these elements.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
The hospital pharmacy segment in the topical androgen receptor inhibitors market is anticipated to hold a share of 47% by the end of 2036. Patients seeking topical androgen receptor inhibitors can benefit from the clinical experience and supervision of pharmacists and dermatologists, who are frequently available in hospital pharmacies. The availability of expert guidance boosts patients' trust in the efficiency and appropriate administration of these drugs. Prescription drugs frequently contain tartrogen receptor inhibitors. To guarantee that patients receive the recommended dosage and formulation, hospital pharmacies are essential in the distribution of prescription pharmaceuticals. Given these factors, it is projected that this segment's market will expand.
Our in-depth analysis of the global market includes the following segments:
|
Indication |
|
|
Distribution Channel |
|
North American Market Forecast
Topical androgen receptor inhibitors market in North America is anticipated to hold the largest share of 34% during the forecast period. This is mostly because there aren't many resources available in the region and the demand for cosmetic operations is rising. The main cause was the rising use of aesthetic procedures in the region to improve the appearance of both adult and senior citizens. Male pattern baldness and unwanted hair growth are two cosmetic concerns that are driving up demand for solutions that address them since looks and aesthetics are becoming more and more important in society. It is therefore expected that the market in the North American region will expand.
APAC Market Statistics
Asia Pacific topical androgen receptor inhibitors market is poised to hold the second largest share of 22% during the forecast period. In the coming years, there will likely be significant growth in the Asia-Pacific region. This is a result of an increase in PCOS and hirsutism cases as well as cosmetic operations performed by more people to remove excessive body hair. In the Asia-Pacific, South Korea, China, Japan, and India are the largest markets. This is mostly due to the high diagnostic rates and widespread awareness of laser hair removal procedures in these nations. Another factor contributing to the growth of this market in the Asia-Pacific region is the fact that Japan has the highest number of laser hair removal operations performed worldwide. PCOS, or polycystic ovarian syndrome, is increasingly frequent in women and can cause hirsutism. This is the primary factor propelling the topical androgen receptor inhibitors market in this region.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?